Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
AstraZeneca
Johnson and Johnson
UBS
Merck
Argus Health
Baxter
Covington
Deloitte

Generated: February 22, 2018

DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

Summary for Eli Lilly And Co
International Patents:173
US Patents:13
Tradenames:7
Ingredients:6
NDAs:6
Drug Master File Entries: 37

Drugs and US Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co PROZAC fluoxetine hydrochloride CAPSULE;ORAL 018936-004 Jun 15, 1999 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co PROZAC fluoxetine hydrochloride CAPSULE;ORAL 018936-006 Dec 23, 1992 AB1 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes 6,551,992 ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-004 Sep 28, 2017 RX Yes Yes 7,855,211 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-003 Sep 28, 2017 RX Yes No 7,855,211 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes 8,569,325*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 AB RX Yes No 8,404,703*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Eli Lilly And Co

Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 7/10/2013
➤ Subscribe Topical Solution 30 mg/1.5 mL ➤ Subscribe 1/29/2013

Non-Orange Book US Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,906,028 Stable insulin formulations ➤ Try a Free Trial
8,177,449 Spreading implement ➤ Try a Free Trial
8,357,393 Transdermal delivery rate control using amorphous pharmaceutical compositions ➤ Try a Free Trial
7,427,275 Medication dispensing apparatus with triple screw threads for mechanical advantage ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Eli Lilly And Co Drugs

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2107069/02 Switzerland ➤ Try a Free Trial PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
2013000061 Germany ➤ Try a Free Trial PRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121
90042 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
91022-0 Sweden ➤ Try a Free Trial PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
C0035 France ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121
C/GB96/036 United Kingdom ➤ Try a Free Trial PRODUCT NAME: INSULIN LISPRO, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: CH 53290 19951123; CH 53553 19951123; UK EU/1/96/007/001 19960430; UK EU/1/96/007/002 19960430; UK EU/1/96/007/003 19960430
13/034 Ireland ➤ Try a Free Trial APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
C/GB09/032 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225
2013000062 Germany ➤ Try a Free Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
00596 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Cipla
Argus Health
Chinese Patent Office
Colorcon
Baxter
Cantor Fitzgerald
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot